Blood group antigen a and flow cytometric analysis in resected early-stage non-small cell lung cancer

被引:0
|
作者
Graziano, SL
Tatum, AH
Gonchoroff, NJ
Newman, NB
Kohman, LJ
机构
[1] VET AFFAIRS MED CTR,DEPT PATHOL,SYRACUSE,NY 13210
[2] VET AFFAIRS MED CTR,DEPT SURG,SYRACUSE,NY 13210
[3] SUNY HLTH SCI CTR,SYRACUSE,NY 13210
关键词
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The loss of blood group antigen A on tumor tissue has been reported to be a strong adverse prognostic marker for patients with resected non-small cell lung cancer (NSCLC), Results have varied with respect to the prognostic significance of flow cytometric data, We sought to confirm the prognostic significance of blood group antigen A loss and flow cytometry in a large cohort of patients with early-stage NSCLC. Two hundred and sixty patients with surgically resected stage I(n = 193) and II (rt = 67) NSCLC with at least a 5-year follow-up were identified, Using paraffin-embedded primary tumor, immunohistochemical stains for blood group antigen A were performed on 90 patients with blood type A or AB, The DNA index and percentage of cells in S phase were successfully obtained on 188 and 152 patients, respectively, The median survival time of the patients with primary tumors negative for blood group antigen A was 38 months (II = 36), compared with 98 months (n = 54) for those with antigen A-positive tumors (P < 0.01), The median disease-free survival times for antigen A-negative and -positive tumors were 26 months and 98 months, respectively (P < 0.01), The median survival time of the patients with aneuploid tumors was 51 months (n = 131), compared with 50 months (n = 57) for those with diploid tumors (P = 0.42), The median survival time of the patients with S phase >8% was 44 months (n = 105), compared with 60 months (n = 47) for those with S phase less than or equal to 8% (P = 0.18), Multivariate analysis showed that the loss of antigen A, higher N and T stages, and the presence of mucin predicted for poorer disease-free and overall survival, In the subgroup of patients with blood group A or AB, the loss of antigen was the most powerful negative predictor of survival, Aneuploidy and percentage of cells in S phase were not of prognostic significance in this group of patients with resected stage I and II NSCLC. The value of blood group antigen A analysis needs to be evaluated in larger and prospective studies of early-stage NSCLC, Alteration of blood group antigen cell surface expression may represent an important marker for more aggressive biological and metastatic behavior in NSCLC.
引用
收藏
页码:87 / 93
页数:7
相关论文
共 50 条
  • [31] Health behaviors of early-stage non-small cell lung cancer survivors
    Krebs, Paul
    Coups, Elliot J.
    Feinstein, Marc B.
    Burkhalter, Jack E.
    Steingart, Richard M.
    Logue, Amy
    Park, Bernard J.
    Ostroff, Jamie S.
    JOURNAL OF CANCER SURVIVORSHIP, 2012, 6 (01) : 37 - 44
  • [32] Progress in the Treatment and Outcomes for Early-Stage Non-Small Cell Lung Cancer
    Shin, Jacob Y.
    Yoon, Ja Kyoung
    Marwaha, Gaurav
    LUNG, 2018, 196 (03) : 351 - 358
  • [33] Neoadjuvant and Adjuvant Immunotherapy in Early-Stage Non-Small Cell Lung Cancer
    Shukla, Nikhil
    Hanna, Nasser
    LUNG CANCER-TARGETS AND THERAPY, 2021, 12 : 51 - 60
  • [34] Is Brain MRI Unnecessary for Early-Stage Non-Small Cell Lung Cancer?
    Bizzi, Alberto
    Pascuzzo, Riccardo
    RADIOLOGY, 2022, 303 (03) : 644 - 645
  • [35] Disparities in surgical resection of early-stage non-small cell lung cancer
    Jazieh, AR
    Kyasa, MJ
    Sethuraman, G
    Howington, J
    JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2002, 123 (06): : 1173 - 1176
  • [36] Waiting times in early-stage non-small cell lung cancer (NSCLC)
    Saint-Jacques, Nathalie
    Rayson, Daniel
    Al-Fayea, Turki
    Virik, Kiran
    Morzycki, Wojciech
    Younis, Tallal
    JOURNAL OF THORACIC ONCOLOGY, 2008, 3 (08) : 865 - 870
  • [37] EARLY-STAGE NON-SMALL CELL LUNG CANCER STRATIFYING RECURRENCE RISK
    Saito, T.
    Kono, Y.
    Ueno, Y.
    Maru, N.
    Utsumi, T.
    Matsui, H.
    Taniguchi, Y.
    Hino, H.
    Tsuta, K.
    Honda, O.
    Murakawa, T.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S559 - S560
  • [38] Adjuvant Chemotherapy in Patients With Early-Stage Non-Small Cell Lung Cancer
    Inamura, Kentaro
    JAMA ONCOLOGY, 2021, 7 (04) : 637 - 638
  • [39] Docetaxel in neoadjuvant therapy of early-stage non-small cell lung cancer
    Betticher, DC
    ONKOLOGIE, 2003, 26 : 33 - 36
  • [40] Progress in the Management of Early-Stage Non-Small Cell Lung Cancer in 2017
    Donington, Jessica S.
    Kim, Young Tae
    Tong, Betty
    Moreira, Andre L.
    Bessich, Jamie
    Weiss, Kathleen D.
    Colson, Yolonda L.
    Wigle, Dennis
    Osarogiagbon, Raymond U.
    Zweig, Jeffrey
    Wakelee, Heather
    Blasberg, Justin
    Daly, Megan
    Backhus, Leah
    Van Schil, Paul
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (06) : 767 - 778